![](https://medcitynews.com/wp-content/uploads/sites/7/2021/07/GettyImages-1290118946.jpg)
EY: 65% of Healthcare Organizations Have Seen a Positive Return on Health Equity Efforts
A new report from Ernst & Young revealed that healthcare organizations are seeing financial benefits and improved outcomes from their health equity strategies.
A new report from Ernst & Young revealed that healthcare organizations are seeing financial benefits and improved outcomes from their health equity strategies.
The industry faces challenges from inflation to labor shortages, according to an annual report from EY. However, there are grounds for optimism and areas to focus on, such as patching up supply chains.
Medical technology companies saw 288 deals between June 2020 and June 2021, the highest amount ever since Ernst & Young began tracking it in 2007. VC funding in medtech also reached a high point of $9.1 billion.
An EY survey of 347 physicians and healthcare executives found respondents have undertaken staff satisfaction-related projects and are planning initiatives around analytics.
Hospitals and health systems face multiple challenges as they transition away from fee-for-service models and toward value-based care. A new survey from EY dug deeper into this issue.
Despite reimbursement, regulatory, and political uncertainty, the global biotech industry held steady in 2016, according to a new report by professional services firm EY (formerly Ernst & Young).
Zelis CEO Amanda Eisel shares her perspective on how the company is solving the problems of a fragmented health financial system to benefit all.
Plus, coverage of BIO 2016, progress on health IT interoperability and a fundraise for a concierge care startup.
As Ernst & Young noted on several occasions, the biotech sector has matured and must now face adult problems.
The lack of innovation in the medical device industry can be attributed to the lessening dollars being funneled into startups, a new report from Ernst & Young says.
Diminished resources and fierce competition from growing biotech and specialty pharma companies will drive smaller and more selective M&A deals by Big Pharma companies in 2013 and beyond. That’s the thesis that Ernst & Young’s life sciences team put forth in a new report called Closing the gap? Big pharma’s growth challenges and implications for […]
The medical device industry, long the backbone of Minnesota's high tech economy, faces perhaps its most challenging environment in decades. From regulatory headaches and health care reform to a dearth of venture capital, medical device stakeholders face a swirling mix of uncertainty and anxiety.